Feasibility Study of Tolerogenic Fibroblasts in Patients With Refractory Multiple Sclerosis

EARLY_PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 21, 2020

Primary Completion Date

June 8, 2021

Study Completion Date

June 8, 2021

Conditions

Multiple Sclerosis, Relapsing-RemittingMultiple Sclerosis

Interventions

BIOLOGICAL

Tolerogenic Fibroblasts

administrating single dose of 100 million tolerogenic fibroblasts via intravenous infusion

Trial Locations (1)

Servicios Medicos UCC, S.C., Tijuana